WO2000025754A3 - Solid oral dosage forms containing alginic acid and famotidine - Google Patents
Solid oral dosage forms containing alginic acid and famotidine Download PDFInfo
- Publication number
- WO2000025754A3 WO2000025754A3 PCT/US1999/025250 US9925250W WO0025754A3 WO 2000025754 A3 WO2000025754 A3 WO 2000025754A3 US 9925250 W US9925250 W US 9925250W WO 0025754 A3 WO0025754 A3 WO 0025754A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alginic acid
- famotidine
- oral dosage
- solid oral
- dosage forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU14536/00A AU1453600A (en) | 1998-11-04 | 1999-11-03 | Solid oral dosage forms containing alginic acid and famotidine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10704598P | 1998-11-04 | 1998-11-04 | |
US06/107,045 | 1998-11-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000025754A2 WO2000025754A2 (en) | 2000-05-11 |
WO2000025754A3 true WO2000025754A3 (en) | 2000-09-08 |
Family
ID=22314559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/025250 WO2000025754A2 (en) | 1998-11-04 | 1999-11-03 | Solid oral dosage forms containing alginic acid and famotidine |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1453600A (en) |
WO (1) | WO2000025754A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0974366T3 (en) | 1997-03-28 | 2007-01-29 | Eisai Co Ltd | Oral pharmaceutical preparations with reduced bitterness by masking |
ATE437632T1 (en) | 2000-03-01 | 2009-08-15 | Eisai R&D Man Co Ltd | RAPID DISRUPTING POLYVINYL TABLET |
US6623785B2 (en) * | 2001-06-07 | 2003-09-23 | Hewlett-Packard Development Company, L.P. | Pharmaceutical dispensing apparatus and method |
WO2005065639A2 (en) * | 2003-11-21 | 2005-07-21 | Torrent Pharmaceuticals Limited | Novel pharmaceutical compositions |
ES2643087T3 (en) | 2010-03-29 | 2017-11-21 | Ferring B.V. | Quick Dissolve Pharmaceutical Composition |
JO3112B1 (en) | 2010-03-29 | 2017-09-20 | Ferring Bv | A fast dissolving pharmaceutical composition |
WO2013037708A1 (en) | 2011-09-16 | 2013-03-21 | Ferring B.V. | A fast dissolving pharmaceutical composition |
WO2017091166A1 (en) * | 2015-11-26 | 2017-06-01 | Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. | Stable pharmaceutical compositions and process for their preparation |
CA3214612A1 (en) * | 2021-03-24 | 2022-09-29 | Johnson & Johnson Consumer Inc. | A pharmaceutical composition comprising famotidine |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260072A (en) * | 1990-08-30 | 1993-11-09 | Mcneil-Ppc, Inc. | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets |
EP0600725A1 (en) * | 1992-12-01 | 1994-06-08 | McNEIL-PPC, INC. | Pharmaceutical compositions containing a guanidinothiazole and antacids |
WO1995001780A1 (en) * | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | H2 antagonist-alginate combinations |
WO1995001795A1 (en) * | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | H2 antagonist-alginate-antacid combinations |
WO1996015775A1 (en) * | 1994-11-21 | 1996-05-30 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
-
1999
- 1999-11-03 AU AU14536/00A patent/AU1453600A/en not_active Abandoned
- 1999-11-03 WO PCT/US1999/025250 patent/WO2000025754A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260072A (en) * | 1990-08-30 | 1993-11-09 | Mcneil-Ppc, Inc. | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets |
EP0600725A1 (en) * | 1992-12-01 | 1994-06-08 | McNEIL-PPC, INC. | Pharmaceutical compositions containing a guanidinothiazole and antacids |
WO1995001780A1 (en) * | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | H2 antagonist-alginate combinations |
WO1995001795A1 (en) * | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | H2 antagonist-alginate-antacid combinations |
WO1996015775A1 (en) * | 1994-11-21 | 1996-05-30 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
Also Published As
Publication number | Publication date |
---|---|
WO2000025754A2 (en) | 2000-05-11 |
AU1453600A (en) | 2000-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999044581A3 (en) | Pharmaceutical composition of topiramate | |
WO1997038679A3 (en) | Fast disintegrating oral dosage form | |
CA2427815A1 (en) | Controlled release hydrocodone formulations | |
WO2001027119A3 (en) | Substance library containing bicyclic imidazo-5-yl-amines and/or bicyclic imidazo-3-yl-amines | |
PT1441705E (en) | Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs | |
PL356358A1 (en) | Solid dosage form of someticone for oral administration | |
HUP0302131A2 (en) | Pharmaceutical tramadol salts, pharmaceutical compositions containing them | |
EE04800B1 (en) | Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form | |
WO2001001973A8 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
IL135130A0 (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
MXPA03006476A (en) | Pharmaceutical dosage forms of epothilones for oral administration. | |
EP1029540A3 (en) | Use of droloxifene for the treatment of cardiovascular diseases | |
WO2002094774A3 (en) | Oxcarbazepine dosage forms | |
WO2001098279A3 (en) | Bis-arylsulfones | |
WO2001097805A3 (en) | Solid valsartan pharmaceutical compositions | |
WO2000025754A3 (en) | Solid oral dosage forms containing alginic acid and famotidine | |
EP1440691A3 (en) | Treatment of neurotic disorders | |
IE852927L (en) | Preparation of silibinin | |
WO2001000617A3 (en) | Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same | |
WO2003037863A3 (en) | Substituted indoles, method for production and use thereof for the inhibition of pain | |
EP0104826A3 (en) | Immunomodulator and method of use for immunomodulation | |
WO2002007716A3 (en) | Method for treating angina | |
AU4976599A (en) | Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives | |
UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine | |
HUP0400495A3 (en) | Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 14536 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |